Malignancies after kidney transplantation

M. Rascente, F. Pisani, A. Barletta, M. D'Angelo, A. Giammaria, I. Parzanese, V. Rizza, G. Iaria, A. Famulari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The most effective treatment of end-stage renal disease is renal transplantation; its superiority to prolong the longevity of patients is well established. Patient and graft survivals have improved with more potent immunosuppression but this advance has been associated with an increased incidence of cancer. The aim of this study was to assess the prevalence of cancer among 265 kidney transplant recipients engrafted between 1968 and October 2004. The overall prevalence of de novo malignancies was 3%. The mean age at diagnosis was 53.3 years (range, 28-63 years) and the duration of the transplant was 11.6 years (range, 0.3-33 years). One patient among 127 (0.8%) who had a history of less than 3 years under immunosuppression, developed a posttransplantation lymphoproliferative disorder (PTLD). Among the 138 patients who had more than 3 years immunosuppression, 7 (5%) developed neoplasms of vulva, colon, native kidneys, prostatic gland, and ovary. One patient was affected by de novo carcinoma in the transplanted kidney. Compared with other published studies, our early cancer prevalence is low, possibly due to a careful history before grafting, good HLA matching, and abstinence from anti-T-cell therapy for treatment of acute rejection episodes. The low level of immunosuppression may account for the low prevalence of neoplasia. The risk of developing a malignancy increases with long-term immunosuppression, comparable with most reports.

Original languageEnglish
Pages (from-to)2529-2531
Number of pages3
JournalTransplantation Proceedings
Volume37
Issue number6
DOIs
Publication statusPublished - 2005

Fingerprint

Kidney Transplantation
Immunosuppression
Neoplasms
Kidney
Vulvar Neoplasms
Lymphoproliferative Disorders
Graft Survival
Cell- and Tissue-Based Therapy
Colonic Neoplasms
Chronic Kidney Failure
Ovary
History
Carcinoma
T-Lymphocytes
Transplants
Incidence
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Rascente, M., Pisani, F., Barletta, A., D'Angelo, M., Giammaria, A., Parzanese, I., ... Famulari, A. (2005). Malignancies after kidney transplantation. Transplantation Proceedings, 37(6), 2529-2531. https://doi.org/10.1016/j.transproceed.2005.06.064

Malignancies after kidney transplantation. / Rascente, M.; Pisani, F.; Barletta, A.; D'Angelo, M.; Giammaria, A.; Parzanese, I.; Rizza, V.; Iaria, G.; Famulari, A.

In: Transplantation Proceedings, Vol. 37, No. 6, 2005, p. 2529-2531.

Research output: Contribution to journalArticle

Rascente, M, Pisani, F, Barletta, A, D'Angelo, M, Giammaria, A, Parzanese, I, Rizza, V, Iaria, G & Famulari, A 2005, 'Malignancies after kidney transplantation', Transplantation Proceedings, vol. 37, no. 6, pp. 2529-2531. https://doi.org/10.1016/j.transproceed.2005.06.064
Rascente M, Pisani F, Barletta A, D'Angelo M, Giammaria A, Parzanese I et al. Malignancies after kidney transplantation. Transplantation Proceedings. 2005;37(6):2529-2531. https://doi.org/10.1016/j.transproceed.2005.06.064
Rascente, M. ; Pisani, F. ; Barletta, A. ; D'Angelo, M. ; Giammaria, A. ; Parzanese, I. ; Rizza, V. ; Iaria, G. ; Famulari, A. / Malignancies after kidney transplantation. In: Transplantation Proceedings. 2005 ; Vol. 37, No. 6. pp. 2529-2531.
@article{d183394654164d3d9a9c6b09d265de08,
title = "Malignancies after kidney transplantation",
abstract = "The most effective treatment of end-stage renal disease is renal transplantation; its superiority to prolong the longevity of patients is well established. Patient and graft survivals have improved with more potent immunosuppression but this advance has been associated with an increased incidence of cancer. The aim of this study was to assess the prevalence of cancer among 265 kidney transplant recipients engrafted between 1968 and October 2004. The overall prevalence of de novo malignancies was 3{\%}. The mean age at diagnosis was 53.3 years (range, 28-63 years) and the duration of the transplant was 11.6 years (range, 0.3-33 years). One patient among 127 (0.8{\%}) who had a history of less than 3 years under immunosuppression, developed a posttransplantation lymphoproliferative disorder (PTLD). Among the 138 patients who had more than 3 years immunosuppression, 7 (5{\%}) developed neoplasms of vulva, colon, native kidneys, prostatic gland, and ovary. One patient was affected by de novo carcinoma in the transplanted kidney. Compared with other published studies, our early cancer prevalence is low, possibly due to a careful history before grafting, good HLA matching, and abstinence from anti-T-cell therapy for treatment of acute rejection episodes. The low level of immunosuppression may account for the low prevalence of neoplasia. The risk of developing a malignancy increases with long-term immunosuppression, comparable with most reports.",
author = "M. Rascente and F. Pisani and A. Barletta and M. D'Angelo and A. Giammaria and I. Parzanese and V. Rizza and G. Iaria and A. Famulari",
year = "2005",
doi = "10.1016/j.transproceed.2005.06.064",
language = "English",
volume = "37",
pages = "2529--2531",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Malignancies after kidney transplantation

AU - Rascente, M.

AU - Pisani, F.

AU - Barletta, A.

AU - D'Angelo, M.

AU - Giammaria, A.

AU - Parzanese, I.

AU - Rizza, V.

AU - Iaria, G.

AU - Famulari, A.

PY - 2005

Y1 - 2005

N2 - The most effective treatment of end-stage renal disease is renal transplantation; its superiority to prolong the longevity of patients is well established. Patient and graft survivals have improved with more potent immunosuppression but this advance has been associated with an increased incidence of cancer. The aim of this study was to assess the prevalence of cancer among 265 kidney transplant recipients engrafted between 1968 and October 2004. The overall prevalence of de novo malignancies was 3%. The mean age at diagnosis was 53.3 years (range, 28-63 years) and the duration of the transplant was 11.6 years (range, 0.3-33 years). One patient among 127 (0.8%) who had a history of less than 3 years under immunosuppression, developed a posttransplantation lymphoproliferative disorder (PTLD). Among the 138 patients who had more than 3 years immunosuppression, 7 (5%) developed neoplasms of vulva, colon, native kidneys, prostatic gland, and ovary. One patient was affected by de novo carcinoma in the transplanted kidney. Compared with other published studies, our early cancer prevalence is low, possibly due to a careful history before grafting, good HLA matching, and abstinence from anti-T-cell therapy for treatment of acute rejection episodes. The low level of immunosuppression may account for the low prevalence of neoplasia. The risk of developing a malignancy increases with long-term immunosuppression, comparable with most reports.

AB - The most effective treatment of end-stage renal disease is renal transplantation; its superiority to prolong the longevity of patients is well established. Patient and graft survivals have improved with more potent immunosuppression but this advance has been associated with an increased incidence of cancer. The aim of this study was to assess the prevalence of cancer among 265 kidney transplant recipients engrafted between 1968 and October 2004. The overall prevalence of de novo malignancies was 3%. The mean age at diagnosis was 53.3 years (range, 28-63 years) and the duration of the transplant was 11.6 years (range, 0.3-33 years). One patient among 127 (0.8%) who had a history of less than 3 years under immunosuppression, developed a posttransplantation lymphoproliferative disorder (PTLD). Among the 138 patients who had more than 3 years immunosuppression, 7 (5%) developed neoplasms of vulva, colon, native kidneys, prostatic gland, and ovary. One patient was affected by de novo carcinoma in the transplanted kidney. Compared with other published studies, our early cancer prevalence is low, possibly due to a careful history before grafting, good HLA matching, and abstinence from anti-T-cell therapy for treatment of acute rejection episodes. The low level of immunosuppression may account for the low prevalence of neoplasia. The risk of developing a malignancy increases with long-term immunosuppression, comparable with most reports.

UR - http://www.scopus.com/inward/record.url?scp=25144444989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144444989&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2005.06.064

DO - 10.1016/j.transproceed.2005.06.064

M3 - Article

C2 - 16182735

AN - SCOPUS:25144444989

VL - 37

SP - 2529

EP - 2531

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 6

ER -